GSK plc
bepirovirsen
chronic hepatitis B
Resolved
102days ago
FDA decision · ~ Mar 27, 2026 estimated
What's at stake
The FDA's approval decision on bepirovirsen for chronic hepatitis B is due ~ Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO), for the treatment ”